Early Phase 1 Immune Clinical Trials
35 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–20 of 35 trials
Recruiting
Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Early Phase 1
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases
Autoimmune
Neukio Biotherapeutics (Shanghai) Co., Ltd.8 enrolled1 locationNCT07144462
Recruiting
Early Phase 1
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
Systemic Lupus ErythematosusAutoimmune Hemolytic Anemia, AIHA
Circunited BioPharma (Shenzhen) Co., Ltd.5 enrolled1 locationNCT07629596
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Diseases
Vivacta Biotechnology (Shanghai) Co., Ltd.22 enrolled1 locationNCT07614191
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology22 enrolled1 locationNCT07333118
Recruiting
Early Phase 1
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Early Phase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Early Phase 1
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
Autoimmune
Janux Therapeutics60 enrolled1 locationNCT07291323
Recruiting
Early Phase 1
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
Auto Immune Disease
Grit Biotechnology30 enrolled1 locationNCT07132112
Recruiting
Early Phase 1
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
AIHA - Warm Autoimmune Hemolytic AnemiaUCART
The Second Hospital of Anhui Medical University15 enrolled1 locationNCT07530380
Recruiting
Early Phase 1
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Early Phase 1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
Autoimmune Diseases
Ruijin Hospital66 enrolled3 locationsNCT06747156
Recruiting
Early Phase 1
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Beijing Boren Hospital18 enrolled1 locationNCT07448298
Recruiting
Early Phase 1
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
Sjogren's SyndromeAutoimmune DiseasesIdiopathic Inflammatory Myopathies+3 more
Nanjing Bioheng Biotech Co., Ltd.20 enrolled1 locationNCT06548607
Recruiting
Early Phase 1
Clinical Study of AFN50 Injection in the Autoimmune Diseases
Autoimmune Diseases
AlphaNa Bioscience Company Limited18 enrolled1 locationNCT07408336
Recruiting
Early Phase 1
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
Neurological Autoimmune Diseases
Juventas Cell Therapy Ltd.18 enrolled1 locationNCT07275736
Recruiting
Early Phase 1
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
Autoimmune Hemolytic AnemiaEvans SyndromePrimary Immune Thrombocytopenic Purpura
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology27 enrolled1 locationNCT07441525
Recruiting
Early Phase 1
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting
Early Phase 1
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
Immune Effector Cell Associated Hematotoxicity
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT07212335
Recruiting
Early Phase 1
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital36 enrolled1 locationNCT07241468